# Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

> clinical trial · VERIFIED · 2026-08-05

Status: COMPLETED · Sponsor: Chongqing Precision Biotech Co., Ltd · Condition: Acute Myeloid Leukemia

- Company: Chongqing Precision Biotech Co., Ltd
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06006403

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.